A Prospective Cohort Interventional Study Assessing the Safety and Outcome of Unani Medicine as a Prophylaxis in Population at risk of COVID-19

Ministry of AYUSH Government of India0 个研究点目标入组 4,500 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Population as described in High/Moderate/Low Risk
•2. Individuals who are from the identified containment zone/ quarantine facility with at least 1 confirmed COVID-19 positive case.
•3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

•1. Persons with severe primary respiratory disease or related complications that may be identified with COVID-19
•2. Laboratory confirmed COVID-19 with or without symptoms
•3. Pregnant and lactating mothers and those who have a pregnancy plan.
•4. Persons with serious critical illness, or severe mental illnesses
•5. Individuals with uncontrolled, unstable co-morbidities
•6. Immuno-compromised individuals or those on immune-suppressants and steroids
•7. Subjects having a past history of allergy to any medicine that is part of the Unani intervention

发起方

Ministry of AYUSH Government of India